CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 406 enrolled
Drug / intervention
Prospekta +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04552041
NCT04552041Phase 3Completed

Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.

Materia Medica Holding·interventional·Posted Sep 17, 2020·Updated Oct 28, 2024

In Brief

A Phase 3 clinical trial evaluating Prospekta and Placebo for Vascular Dementia. Completed, enrolled 406 participants across 33 sites.

Detailed Summary

Study purpose: \- evaluate clinical efficacy ands afety of Prospekta in the treatment of cognitive, behavioral and psychiatric disorders in patients with vascular dementia. Study objectives: * evaluate and compare changes in cognitive functions, in behavioral and in psychiatric dementia symptoms in Prospekta and Placebo groups after 24-weeks of treatment * evaluate and compare the frequency, severity and causal relationship of adverse events (AEs) with the type of therapy in Prospekta and Placebo groups (including central nervous system AEs during therapy, their relationship with the study drug and other characteristics).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedSep 17, 2020
Enrollment StartDec 3, 2020
Primary CompletionSep 22, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.8 years ago

Interventions

Prospektadrug

Oral administration.

Placebodrug

Oral administration.